Bovie Medical to Present at 28th Annual Piper Jaffray Healthcare Conference

Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that Robert L. Gershon, Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 12:50 p.m. ET at the Lotte New York Palace in New York.

The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Bovie Medical’s website at http://www.boviemedical.com/investor_relations/ in the “Presentations” section.

Investors attending the conference may arrange a one-on-one meeting with Bovie Medical management by contacting Piper Jaffray.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161123005109/en/

Investor Relations:MBS Value PartnersLynn Morgen / Jane [e-mail]